ResMed Shares Hold Steady as CFO Sale, 144 Filing Confirm Corporate Stability
ResMed’s shares hover near a $300 target as CFO’s sale and Form 144 filings show routine insider activity, while strong product pipeline and solid assets keep the company positioned for long‑term growth in sleep‑apnea devices.
3 minutes to read









